News Focus
News Focus
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: hemidriver post# 21061

Saturday, 03/24/2018 12:53:14 AM

Saturday, March 24, 2018 12:53:14 AM

Post# of 236715
R/s is needed. Look at all the good news that has come. With all the good news, especially the phase 3 combo data for HIV should have put us at least at $2 per share. the OTC is built on NITE and CANT shorting stocks and manipulating share price.

Most other biotechs that did a r/s were not this far along. They were only in phase 1 or phase 2 that I have seen in the past. LJPC uplisted when it was only in a phase 2. The thing is that Cytodyn has already passed a phase 3 combo for HIV that's huge. I think as soon as it gets on the NASDAQ institutions may buy in. It has to happen otherwise not even BLA news is going to move the stock on the OTC.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News